REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases
Portfolio Pulse from
REGENXBIO and Nippon Shinyaku have formed an exclusive partnership to develop and commercialize gene therapies RGX-121 and RGX-111 for MPS diseases. REGENXBIO will receive $110 million upfront, potential milestone payments up to $700 million, and double-digit royalties. Nippon Shinyaku will lead commercialization in the U.S. and Asia.
January 14, 2025 | 10:15 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
REGENXBIO has partnered with Nippon Shinyaku to develop and commercialize RGX-121 and RGX-111, receiving $110 million upfront and potential milestone payments up to $700 million. This partnership could significantly boost REGENXBIO's financials and market presence.
The partnership with Nippon Shinyaku provides REGENXBIO with substantial upfront and potential milestone payments, enhancing its financial position. The collaboration also expands its market reach in the U.S. and Asia, potentially increasing future revenues.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100